Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor
- PMID: 1701568
- DOI: 10.1126/science.1701568
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor
Erratum in
- Science 1991 Jan 25;251(4992):362
Abstract
A series of dipyridodiazepinones have been shown to be potent inhibitors of human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT). One compound, BI-RG-587, had a Ki of 200 nanomolar for inhibition of HIV-1 RT that was noncompetitive with respect to deoxyguanosine triphosphate. BI-RG-587 was specific for HIV-1 RT, having no effect on feline and simian RT or any mammalian DNA polymerases. BI-RG-587 inhibited HIV-1 replication in vitro as demonstrated by in situ hybridization, inhibition of protein p24 production, and the lack of syncytia formation in cultured human T cell lines and freshly isolated human peripheral blood lymphocytes. Cytotoxicity studies of BI-RG-587 on human cells showed a high therapeutic index (greater than 8000) in culture.
Similar articles
-
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587.J Infect Dis. 1991 May;163(5):966-70. doi: 10.1093/infdis/163.5.966. J Infect Dis. 1991. PMID: 1708400
-
HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.Biochem Pharmacol. 1992 Mar 17;43(6):1371-6. doi: 10.1016/0006-2952(92)90515-k. Biochem Pharmacol. 1992. PMID: 1373283
-
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.Antimicrob Agents Chemother. 1991 Feb;35(2):305-8. doi: 10.1128/AAC.35.2.305. Antimicrob Agents Chemother. 1991. PMID: 1708976 Free PMC article.
-
Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine).Med Res Rev. 1992 Jan;12(1):27-40. doi: 10.1002/med.2610120103. Med Res Rev. 1992. PMID: 1371177 Review. No abstract available.
-
The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.Arch Virol Suppl. 1994;9:11-7. doi: 10.1007/978-3-7091-9326-6_2. Arch Virol Suppl. 1994. PMID: 7518271 Review.
Cited by
-
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development.PLoS One. 2011;6(11):e27518. doi: 10.1371/journal.pone.0027518. Epub 2011 Nov 23. PLoS One. 2011. PMID: 22132107 Free PMC article.
-
Antiviral therapy: current concepts and practices.Clin Microbiol Rev. 1992 Apr;5(2):146-82. doi: 10.1128/CMR.5.2.146. Clin Microbiol Rev. 1992. PMID: 1576586 Free PMC article. Review.
-
L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.Antimicrob Agents Chemother. 1992 May;36(5):1019-23. doi: 10.1128/AAC.36.5.1019. Antimicrob Agents Chemother. 1992. PMID: 1380788 Free PMC article.
-
Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.Paediatr Drugs. 2000 Sep-Oct;2(5):373-407. doi: 10.2165/00128072-200002050-00005. Paediatr Drugs. 2000. PMID: 11022799 Review.
-
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7188-93. doi: 10.1073/pnas.121055998. Proc Natl Acad Sci U S A. 2001. PMID: 11416202 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources